Table 1 Baseline characteristics
Variables | Usual care group (n = 42) | VAC-optimized group (n = 40) |
|---|---|---|
Age (years), mean ± SD | 70 ± 12 | 68 ± 16 |
Male/Female, n | 24/18 | 22/18 |
Body mass index (kg/m2), mean ± SD | 22.9 ± 3.8 | 22.8 ± 3.4 |
APACHE II score at enrollment, mean ± SD | 20 ± 5 | 21 ± 6 |
SOFA score at enrollment, mean ± SD | 9 ± 3 | 9 ± 4 |
Time from ICU admission to randomization (hours), median (IQR) | 2.0 (0.5, 8.5) | 2.0 (1.0, 10.8) |
Comorbidities, n (%) | ||
Hypertension | 14 (33) | 19 (48) |
Diabetes | 12 (29) | 8 (20) |
Chronic obstructive pulmonary disease | 6 (14) | 10 (25) |
Chronic kidney disease | 4 (10) | 5 (13) |
Coronary heart disease | 3 (7) | 4 (10) |
Source of infection, n (%) | ||
Lung | 21 (50) | 23 (58) |
Abdomen | 10 (24) | 8 (20) |
Digestive tract | 9 (21) | 6 (15) |
Bloodstream | 9 (21) | 2 (5)* |
Urinary tract | 2 (5) | 7 (18) |
Others | 4 (10) | 2 (5) |
Invasive mechanical ventilation, n (%) | 27 (64) | 28 (70) |
Ventilator settings, mean ± SD | ||
Tidal volume (mL/kg of PBW) | 8.3 ± 2.0 | 8.2 ± 2.3 |
Driving pressure (cmH2O) | 14 ± 4 | 14 ± 3 |
PEEP (cmH2O) | 6 ± 2 | 7 ± 3 |
Analgesic and sedative drugs, n (%) | ||
Fentanyl | 18 (43) | 16 (40) |
Midazolam | 20 (48) | 18 (45) |
Propofol | 7 (17) | 10 (25) |
Cumulative fluid volume before NE infusion (mL/kg), mean ± SD | 19.0 ± 10.3 | 18.8 ± 10.4 |